Specific Akt3 inhibitor and uses thereof
AssigneeAugusta University Research Institute, Inc.
InventorsSamir N. Khleif, Mikayel Mkrtichyan, Iryna Lebedyeva
Life of this patent
Estimating the term…
Abstract
Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.
Claims9
A method of decreasing an immune suppressive response in a subject in need thereof comprising administering to the subject a composition comprising 0.01 to 50 mg/kg of 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide that selectively inhibits Akt3 by an amount effective to reduce the immune suppressive function of Tregs in the subject.
Dependencies are inferred from the claim text.